Changes in Beneficial Ownership · 4
AbCellera Biologics Inc.
ABCLNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1786647701.xml
Filing details
- Report period
- 2026-08-11
- Issuer
- AbCellera Biologics Inc.
- Issuer CIK
- 0001703057
- Trading symbol
- ABCL
Reporting owner 1
- Name
- Hayden Michael R
- Reporting owner CIK
- 0001352908
- Relationship
- Director
- Address
- C/O ABCELLERA BIOLOGICS INC, 150 W 4TH AVENUE, VANCOUVER, BRITISH COLUMBIA, CANADA, A1
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership | Nature of ownership | Timeliness |
|---|---|---|---|---|---|---|---|---|---|
| Common Shares | 2026-08-11 | G · Form 5 | 50,000 | D | 0[F1] | 1,273,397 | I[F2] | See footnote | E |
Table key
- G · Form 5
- Bona fide gift
- D
- Disposed
- I
- Indirect
Non-derivative holdings
| Security | Amount owned | Ownership | Nature of ownership |
|---|---|---|---|
| Common Shares | 118,245 | I | By spouse |
Table key
- I
- Indirect
Footnotes
- F1
- This transaction represents a charitable donation of 50,000 common shares made by Genworks 2 Consulting, Inc. on August 11, 2026.↩ 1
- F2
- These shares are held by Genworks 2 Consulting, Inc. The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2 Consulting, Inc. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein.↩ 1
Signature 1
- Signed
- Tryn Stimart, attorney-in-fact
- Date
- 2026-08-13
Company context
AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women’s health, immunology, oncology, and more.